长春高新：子公司注射用GenSci143境外生产药品注册临床试验申请获受理

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical Co., has received written notification from the FDA regarding the acceptance of the clinical trial application for GenSci143, a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA, indicating potential dual therapeutic effects in chemotherapy and tumor immunotherapy [1] Company Summary - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, is advancing its clinical trial for GenSci143, which is a self-developed drug [1] - The drug GenSci143 is designed to target both B7-H3 and PSMA, showcasing its innovative approach in cancer treatment [1] Industry Summary - The acceptance of the clinical trial application by the FDA highlights the growing interest and investment in dual-specific antibody-drug conjugates within the pharmaceutical industry [1] - The potential dual therapeutic effects of GenSci143 may position it favorably in the competitive landscape of cancer therapies [1]